AU2010315361B2 - Quinazoline compounds - Google Patents

Quinazoline compounds Download PDF

Info

Publication number
AU2010315361B2
AU2010315361B2 AU2010315361A AU2010315361A AU2010315361B2 AU 2010315361 B2 AU2010315361 B2 AU 2010315361B2 AU 2010315361 A AU2010315361 A AU 2010315361A AU 2010315361 A AU2010315361 A AU 2010315361A AU 2010315361 B2 AU2010315361 B2 AU 2010315361B2
Authority
AU
Australia
Prior art keywords
amino
methyl
methyloxy
alkyl
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010315361A
Other languages
English (en)
Other versions
AU2010315361A1 (en
Inventor
Lara S. Kallander
Brian Griffin Lawhorn
Joanne Philp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of AU2010315361A1 publication Critical patent/AU2010315361A1/en
Application granted granted Critical
Publication of AU2010315361B2 publication Critical patent/AU2010315361B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2010315361A 2009-11-03 2010-11-01 Quinazoline compounds Ceased AU2010315361B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25764609P 2009-11-03 2009-11-03
US61/257,646 2009-11-03
PCT/US2010/054927 WO2011056740A1 (en) 2009-11-03 2010-11-01 Quinazoline compounds

Publications (2)

Publication Number Publication Date
AU2010315361A1 AU2010315361A1 (en) 2012-05-24
AU2010315361B2 true AU2010315361B2 (en) 2014-06-12

Family

ID=43970282

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010315361A Ceased AU2010315361B2 (en) 2009-11-03 2010-11-01 Quinazoline compounds

Country Status (13)

Country Link
US (1) US8859571B2 (https=)
EP (1) EP2501233B1 (https=)
JP (1) JP5836963B2 (https=)
KR (1) KR101736521B1 (https=)
CN (1) CN102711474B (https=)
AU (1) AU2010315361B2 (https=)
BR (1) BR112012010524A2 (https=)
CA (1) CA2779989A1 (https=)
EA (1) EA021439B1 (https=)
ES (1) ES2523465T3 (https=)
IL (1) IL219504A (https=)
MX (1) MX2012005155A (https=)
WO (1) WO2011056740A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5603883B2 (ja) * 2009-02-17 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−Ｒａｆキナーゼを阻害するためのピリミドピリミジン誘導体
CN103159685A (zh) * 2013-04-11 2013-06-19 苏州立新制药有限公司 4-氯-6，7-二(2-甲氧基乙氧基)喹唑啉的制备方法
JP6527513B2 (ja) * 2013-11-20 2019-06-05 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍファミリーキナーゼ阻害剤としてのキナゾリン誘導体
CN105849044B (zh) 2013-12-26 2018-10-26 埃克森美孚研究工程公司 Zsm-48晶体的合成
CN111868039A (zh) * 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
JP7785663B2 (ja) 2019-09-16 2025-12-15 ノバルティス アーゲー 二機能性分解誘導薬及びそれらの使用方法
WO2023049312A1 (en) 2021-09-23 2023-03-30 Erasca, Inc. Egfr inhibitor polymorph forms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015814A (en) * 1995-04-27 2000-01-18 Zeneca Limited Quinazoline derivative
US20070259904A1 (en) * 2005-11-01 2007-11-08 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015814A (en) * 1995-04-27 2000-01-18 Zeneca Limited Quinazoline derivative
US20070259904A1 (en) * 2005-11-01 2007-11-08 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases

Also Published As

Publication number Publication date
ES2523465T3 (es) 2014-11-26
US8859571B2 (en) 2014-10-14
JP2013510155A (ja) 2013-03-21
JP5836963B2 (ja) 2015-12-24
CA2779989A1 (en) 2011-05-12
US20120220588A1 (en) 2012-08-30
EP2501233A1 (en) 2012-09-26
EA201290243A1 (ru) 2012-12-28
KR101736521B1 (ko) 2017-05-16
CN102711474A (zh) 2012-10-03
IL219504A (en) 2016-09-29
BR112012010524A2 (pt) 2017-12-12
KR20120112441A (ko) 2012-10-11
EP2501233B1 (en) 2014-09-24
WO2011056740A1 (en) 2011-05-12
MX2012005155A (es) 2012-08-31
CN102711474B (zh) 2014-09-10
AU2010315361A1 (en) 2012-05-24
EA021439B1 (ru) 2015-06-30
IL219504A0 (en) 2012-06-28
EP2501233A4 (en) 2013-06-19

Similar Documents

Publication Publication Date Title
US10717711B2 (en) Amino quinazolines as kinase inhibitors
JP2022081606A (ja) Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物
AU2011205485B2 (en) Compounds and methods
AU2010315361B2 (en) Quinazoline compounds
AU2020302338A1 (en) 2,3-dihydroquinazolin compounds as NAV1.8 inhibitors
AU2022217353B2 (en) Pyridopyrimidinone derivative, preparation method therefor, and use thereof
ES2984158T3 (es) Inhibidores y moduladores de WDR5
WO2011056739A1 (en) Compounds and methods
AU2019230859B2 (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
ES2593057B1 (es) Moduladores selectivos de la actividad del receptor GPR55: derivados de cromenopirazol
EP2470022A1 (en) Compounds and methods
WO2011088031A1 (en) Compounds and methods
CN113880814B (zh) 一种嘧啶胺类化合物及应用
CN113943251B (zh) 双环庚烯基氨基取代的氮杂芳环类化合物及其医药用途
NZ621314B2 (en) Amino quinazolines as kinase inhibitors
HK1195301A (en) Aminopyrimidine derivatives as lrrk2 modulators

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired